“Moving towards individualized therapy in pediatric cancer”

Cure rates for children with cancer have improved to the point that 83% of children diagnosed with cancer in Canada will be cured. However many of these children are left with late effects due to treatment. Moreover there is a subset of children who do not respond to treatment and where no curative therapy is available. With advances in genomic technology, tools are now available to identify genetic variation in both host and tumor that may explain the poor outcomes for some children. This seminar will investigate pharmacogenomics of chemotherapy toxicity, as well as a pilot project looking at tumor genetics and identifying potential drugable targets.